Zevra Therapeutics, Inc. (ZVRA) News
Track canonical SquawkNews coverage tagged to ZVRA, Zevra Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ZVRA: Broader patient reach, data-driven growth, and global expansion drive rare disease strategy
Significant progress includes expanding the diagnosed population for MIPLYFFA, leveraging updated clinical guidelines, and investing in data-driven patient identification. Global expansion and a strong balance sheet supp
NEWS | Sep 15, 2026, 02:53 PM UTC
L
ZVRA: Broader patient identification, global expansion, and data-driven strategy fuel rare disease growth
Significant progress includes expanding the diagnosed population for MIPLYFFA, advancing global and U.S. commercialization, and leveraging robust data and updated guidelines to drive adoption. Strategic investments and a
NEWS | Sep 15, 2026, 02:39 PM UTC
L
ZVRA: Rapid U.S. growth, global expansion, and a strong pipeline drive rare disease innovation
Focused on redefining rare disease care, the company has rapidly grown its U.S. market for Niemann-Pick type C, expanded globally, and advanced a promising pipeline. Strong financials and robust patient support underpin
NEWS | Sep 14, 2026, 11:36 PM UTC
L
ZVRA: Strong U.S. growth, global expansion, and pipeline progress drive rare disease leadership
The organization is rapidly expanding its rare disease portfolio, achieving strong U.S. commercial traction in NPC, and is advancing global and pipeline initiatives. Financial strength and disciplined strategy support gr
NEWS | Sep 14, 2026, 11:28 PM UTC
L
ZVRA: Strong commercial growth, expanding rare disease reach, and robust financials drive future milestones
The organization is rapidly expanding its rare disease portfolio, with strong commercial momentum for its lead therapy, robust patient support, and a growing addressable market. Financial strength and disciplined strateg
NEWS | Sep 14, 2026, 10:33 PM UTC
L
ZVRA highlights U.S. market penetration and pipeline progress
TradingView News says a conference cited significant U.S. market penetration for NPC, robust pipeline progress including VEDS, and a long IP runway supporting rare-disease growth.
EQUITY | Sep 09, 2026, 02:13 PM UTC
L
Zevra Therapeutics executives to present at upcoming investor conferences
Zevra Therapeutics said members of its executive leadership team will present at upcoming investor conferences.
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
ZVRA - Zevra Therapeutics to Present at Upcoming Investor Conferences
ZVRA - Zevra Therapeutics to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA in NPC
Zevra Therapeutics (ZVRA) says it will present new long-term real-world data on MIPLYFFA® for Niemann-Pick disease type C (NPC) at the 2026 SSIEM Annual Symposium.
EQUITY | Aug 25, 2026, 11:30 AM UTC
L
Zevra Therapeutics grants inducement awards under Nasdaq rule
Zevra Therapeutics says it granted inducement awards under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 21, 2026, 08:30 PM UTC
L
Zevra Therapeutics to Present at Conference
Zevra Therapeutics presents at growth conference
EQUITY | Aug 04, 2026, 11:30 AM UTC
M
Zevra Therapeutics Publishes Real-World Data
Zevra publishes 4-year data on MIPLYFFA in NPC
EQUITY | Aug 03, 2026, 11:30 AM UTC
L
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
ZVRA Reiterate Buy, though lower PT to $20 (from $29) after unfortunate European outcome @ Canaccord
EQUITY | Jul 27, 2026, 12:55 PM UTC
L
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C
EQUITY | Jul 24, 2026, 12:08 PM UTC
M
ZVRA: Publishes Positive MIPLYFFA Data
Zevra Therapeutics announces publication of positive MIPLYFFA data from pediatric substudy in infants with Niemann-Pick Disease Type C
EQUITY | Jun 23, 2026, 11:31 AM UTC